Last updated: February 20, 2026
What is NDC 27241-0187?
NDC 27241-0187 refers to a specific drug product registered under the National Drug Code system. The code corresponds to [specific drug name], manufactured by [manufacturer], indicated for [therapeutic use]. As the product target market and competitive landscape are crucial, detailed product information, including formulation, approved indications, and regulatory status, guides market projections.
Market Size and Demand Drivers
Current Market Landscape
The drug primarily competes in [therapy area], with an estimated global market size of approximately USD X billion in 2022. The key drivers include:
- Rising prevalence of [disease/condition]
- Expanded indications following recent approvals
- Growing demand for innovative therapies
Patient Population
Based on recent epidemiological data:
- Estimated number of eligible patients in the U.S.: approximately X million
- Forecasted compound annual growth rate (CAGR): X% over 2023–2028
Competitive Landscape
Major competitors include:
| Brand Name |
Market Share (%) |
Price per unit (USD) |
Year of Market Entry |
| [Competitor A] |
X% |
$X.XX |
YYYY |
| [Competitor B] |
X% |
$X.XX |
YYYY |
| [Product NDC 27241-0187] |
— |
TBD |
Pending approval |
Market entry timing influences competitive positioning. The drug’s FDA or EMA approval status, currently pending or granted, directly impacts its market entry.
Price Trends and Revenue Projections
Current Pricing
The introductory wholesale acquisition cost (WAC) is estimated at roughly USD X per unit, with retail prices typically 10–15% higher. The average treatment course involves X units, translating to initial treatment costs between USD X,XXX and USD X,XXX.
Price Evolution Factors
- Regulatory approvals increase pricing power.
- Manufacturing costs, including complex synthesis or biologic nature if applicable.
- Reimbursement landscape: insurer policies, Medicare/Medicaid coverage, and patient out-of-pocket costs.
- Patent status and exclusivity periods. Patent expiry in YYYY could lead to generic entry.
Revenue Projections (2023–2028)
| Year |
Estimated Units Sold |
Approximate Revenue (USD millions) |
Assumptions |
| 2023 |
X,000 |
$XX |
Launch following approval; initial uptake X% |
| 2024 |
X0,000 |
$XX0 |
Market penetration increases; pricing stabilizes |
| 2025 |
XX0,000 |
$XX0 |
Growth driven by expanded indications/expanding market |
| 2026 |
XXX,000 |
$XXX |
Competition and generic entry influence prices |
| 2027 |
XXX,000 |
$XXX |
Market stabilization around established price points |
Note: Price adjustments likely occur in response to market competition, formulary negotiations, and regulatory decisions.
Regulatory and Policy Impact
- Pending approval decisions in jurisdictions like the EU, Japan, or Canada
- Reimbursement frameworks affecting net sales
- FDA/EMA priority review or orphan drug designation may accelerate market entry and pricing leverage
Key Takeaways
- The drug faces competition from well-established brands, with market entry timing critical.
- Initial pricing is projected between $X to $Y per unit, with potential for increases based on demand and regulatory considerations.
- Sales growth depends on regulatory approval, market penetration, and reimbursement policies.
- The patent landscape and potential for biosimilar or generic competition in the mid-2020s will influence long-term pricing and revenue.
FAQs
1. When is the drug expected to gain regulatory approval?
Approval timing, expected in YYYY, hinges on ongoing clinical trial outcomes and submission status.
2. How does patent expiration impact future pricing?
Patent expiration anticipated around YYYY likely allows generic competitors, reducing prices by 60–80%.
3. What are the main competitive advantages?
Unique formulation, novel mechanism of action, or superior efficacy compared to existing products.
4. How do reimbursement policies influence sales?
Coverage takes crucial importance; favorable reimbursement increases patient access and sales volume.
5. What are the risks to revenue growth?
Delayed approval, unfavorable regulatory decisions, patent challenges, or increased competition could dampen projections.
References
- [Source 1]
- [Source 2]
- [Source 3]
- [Source 4]
- [Source 5]
(Note: Specific references are placeholders; actual data sources should include regulatory filings, market research reports, and industry publications.)
